131 related articles for article (PubMed ID: 18437127)
1. Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study.
Palmieri V; Bella JN; Gerdts E; Wachtell K; Papademetriou V; Nieminen MS; Dahlöf B; Devereux RB
Am J Hypertens; 2008 Jun; 21(6):701-7. PubMed ID: 18437127
[TBL] [Abstract][Full Text] [Related]
2. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
3. Indices of pulse wave analysis are better predictors of left ventricular mass reduction than cuff pressure.
Hashimoto J; Imai Y; O'Rourke MF
Am J Hypertens; 2007 Apr; 20(4):378-84. PubMed ID: 17386343
[TBL] [Abstract][Full Text] [Related]
4. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
[TBL] [Abstract][Full Text] [Related]
5. Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy).
Gerdts E; Björnstad H; Devereux RB; Lund-Jhansen P; Davidsen ES; Omvik P
Blood Press; 2006; 15(4):220-6. PubMed ID: 17060116
[TBL] [Abstract][Full Text] [Related]
6. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Wachtell K; Dahlöf B; Rokkedal J; Papademetriou V; Nieminen MS; Smith G; Gerdts E; Boman K; Bella JN; Devereux RB
Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
[TBL] [Abstract][Full Text] [Related]
7. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
Olsen MH; Wachtell K; Ibsen H; Lindholm LH; Dahlöf B; Devereux RB; Kjeldsen SE; Oikarinen L; Okin PM;
J Hypertens; 2006 Apr; 24(4):775-81. PubMed ID: 16531808
[TBL] [Abstract][Full Text] [Related]
8. Antihypertensive treatment alters the predictive strength of pulse pressure and other blood pressure measures.
Greenberg J
Am J Hypertens; 2005 Aug; 18(8):1033-9. PubMed ID: 16109316
[TBL] [Abstract][Full Text] [Related]
9. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive hemodynamic assessment of the effect of mean arterial pressure on the amplitude of pulse pressure.
Alfie J; Galarza C; Waisman G
Am J Hypertens; 2005 Feb; 18(2 Pt 2):60S-64S. PubMed ID: 15752934
[TBL] [Abstract][Full Text] [Related]
11. Power spectral components of heart rate variability in different types of cardiac remodelling in hypertensive patients.
Konrady AO; Rudomanov OG; Yacovleva OI; Shlyakhto EV
Med Sci Monit; 2001; 7(1):58-63. PubMed ID: 11208494
[TBL] [Abstract][Full Text] [Related]
12. Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy.
Fossum E; Olsen MH; Høieggen A; Wachtell K; Reims HM; Ibsen H; Julius S; Kjeldsen SE
J Hum Hypertens; 2004 Jun; 18(6):375-80. PubMed ID: 15057253
[TBL] [Abstract][Full Text] [Related]
13. Left ventricular geometry and arterial function in hypercholesterolemia.
Celentano A; Crivaro M; Roman MJ; Pietropaolo I; Greco R; Pauciullo P; Lirato C; Devereux RB; de Simone G
Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):312-9. PubMed ID: 11887428
[TBL] [Abstract][Full Text] [Related]
14. Type 2 diabetes is associated with left ventricular concentric remodeling in hypertensive patients.
Eguchi K; Kario K; Hoshide S; Ishikawa J; Morinari M; Shimada K
Am J Hypertens; 2005 Jan; 18(1):23-9. PubMed ID: 15691613
[TBL] [Abstract][Full Text] [Related]
15. Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study).
Gerdts E; Roman MJ; Palmieri V; Wachtell K; Smith G; Nieminen MS; Dahlöf B; Devereux RB
J Hum Hypertens; 2004 Jun; 18(6):417-22. PubMed ID: 15103312
[TBL] [Abstract][Full Text] [Related]
16. Smoking and antihypertensive medication: interaction between blood pressure reduction and arterial stiffness.
Matsui Y; Kario K; Ishikawa J; Hoshide S; Eguchi K; Shimada K
Hypertens Res; 2005 Aug; 28(8):631-8. PubMed ID: 16392766
[TBL] [Abstract][Full Text] [Related]
17. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Dahlöf B; Burke TA; Krobot K; Carides GW; Edelman JM; Devereux RB; Diener HC
J Hum Hypertens; 2004 Jun; 18(6):367-73. PubMed ID: 15029217
[TBL] [Abstract][Full Text] [Related]
18. Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study.
Palmieri V; Bella JN; Roman MJ; Gerdts E; Papademetriou V; Wachtell K; Nieminen MS; Dahlöf B; Devereux RB
J Hypertens; 2003 Apr; 21(4):781-7. PubMed ID: 12658025
[TBL] [Abstract][Full Text] [Related]
19. Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Reims HM; Kjeldsen SE; Brady WE; Dahlöf B; Devereux RB; Julius S; Beevers G; De Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
J Hum Hypertens; 2004 Jun; 18(6):381-9. PubMed ID: 15103313
[TBL] [Abstract][Full Text] [Related]
20. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
Aznaouridis KA; Vyssoulis GP; Karpanou EA; Marinakis AG; Barbetseas JD; Zervoudaki AI; Cokkinos DV; Stefanadis CI
Blood Press Monit; 2007 Apr; 12(2):87-94. PubMed ID: 17353651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
